Professional Documents
Culture Documents
2nd Quarterly Financial Report 2023 JCR Pharma - MPSII
2nd Quarterly Financial Report 2023 JCR Pharma - MPSII
A. Operating results ( please refer to page 3/27 in the Japanese Report for the
original version, extracted part is shown in Figure 1)
2. Main Sales
From 1st Apr 2021 From 1st Apr 2022 Change
to 30th Sep 2021 to 30th Sep 2022
Sales (Million JPY) Sales(Million JPY) %
Growth Hormone 6,689 6,083 -9.1
MPS II Therapy
985 2118 114.8
Izcargo I.V. Infusion
Renal Anemia Therapies 3,011 2,157 -28.4
Epoetin Alfa BS Inj. [JCR] 1,512 1,392 -8.0
Darbepoetin Alfa BS Inj.
1,498 765 -48.9
[JCR]
Regenerative Therapy
1,717 1,701 -0.9
Temcell HS Inj.
Fabry Disease Therapy
Agalsidase Beta 323 521 61.0
BS I.V. Infusion
Contract Revenue 7,557 1,010 -86.6
AZD1222 Active Ingredient 8,046 1,931 -76.0
B. Status of Research and Development (please refer to page 4/27 in the Japanese
Report for the original version, extracted part is shown in Figure 2)
Total research and development expenditure for the first half of the year under
review amounted to JPY 4,216 million (previous half of the year: JPY 3,520 million).
The status of the Group's research and development activities in the first half of
the year under review is described in (1) Operating results.
Development No. Phase Indication Remarks
(Generic Name)
JR-141 Global Phase 3 MPS II Use Enzyme
(Recombinant (Hunter Replacement
blood-brain barrier Syndrome) Therapy [J-Brain
crossing iduronate Cargo]
2-sulfatase)
Omitted Below Omitted Below Omitted Below Omitted Below